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2 Summary 
Vascular Endothelial Growth Factor(VEGF) inhibits endothelial apoptosis through 
upregulation of Poly(ADP-ribose)-Polymerase(PARP) expression. Neuropilin-1(NP-1) 
is an alternative receptor for VEGF and possibly a fine-regulator of the endothelial 
response to ischemia. In the cerebral vasculature the mechanisms of apoptosis 
induction and inhibition are not fully understood. This study investigated the impact of 
NP-1 on endothelial PARP expression and its modulatory role in apoptosis inhibition 
by VEGF.  
VEGF treated endothelial cell cultures showed NP-1 and VEGF-R2 complexing and 
enhanced PARP expression. An inhibition of VEGF/VEGFR-2 interaction on 
apoptosis induced by adhesion inhibition through the DV-integrin inhibitor cRGD was 
augmented. Cerebral ischemia and endothelial apoptosis were investigated by MRI 
and immunohistochemistry in rat models of permanent and temporary middle 
cerebral artery occlusion. Ischemic hemispheres displayed apoptosis and increased 
endothelial NP-1 and VEGFR-2 expression compared to non-ischemic hemispheres 
and sham-operated or untreated controls. Increased SOD-1 and Catalase expression 
indicated oxidative stress in the ischemic brain. Endothelial PARP expression 
remained stable during cerebral ischemia despite pro-apoptotic conditions.  
NP-1 upregulation reinforced apoptosis inhibition and modulated VEGF-dependent 
PARP.  
 
Keywords: Vascular Endothelial Growth Factor Receptor, Neuropilin-1, 
apoptosis,cerebrovascular system, rat middle cerebral artery occlusion (MCAO) 
model 
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3  Zusammenfassung 
Der vaskuläre endotheliale Wachstumsfaktor VEGF hemmmt die 
Endothelzellapoptose über eine Hochregulierung von Poly(ADP-ribose)-
Polymerase(PARP). Neuropilin-1(NP-1) ist ein alternativer Rezeptor für VEGF und 
möglicherweise ein Feinregulator der Endothelantwort bei zerebraler Ischämie. Der 
Mechanismus der Apoptoseinduktion und ±hemmung in zerebralen Gefäßen ist noch 
ungeklärt. Diese Studie untersucht den Einfluss von NP-1 auf die endotheliale PARP 
Expression und seine Rolle bei Apoptoseinhibierung durch VEGF. 
Mit VEGF behandelte Endothelzellkulturen zeigten Komplexierung von NP-1 und 
VEGFR-2 sowie erhöhte PARP-Expression. Eine Hemmung der VEGF/VEGF-R2 
Interaktion bei Apoptose wurde beobachtet. Zerebrale Ischämie und endotheliale 
Apoptose wurden anhand eines Rattenmodels durch temporäre und permanente 
Okklusion der A.cerebri media mittels MRT und Immunhistochemie untersucht. 
Ischämische Hemisphären wiesen neben Apoptose erhöhte NP-1 und VEGFR-2 
Expression im Vergleich zu nicht ischämischen Hemisphären und Sham-operierten 
Tieren oder unbehandelten Kontrollen auf. 
Erhöhte SOD-1 und Catalase-Expression indizierten oxidativen Stress bei Ischämie. 
Die endotheliale PARP Expression blieb während Ischämie trotz proapoptotischer 
Bedingungen stabil.  
Die Hochregulierung von NP-1 verstärkt die Apoptosehemmung und moduliert 
VEGF-abhängig die PARP-Expression.  
 
Schlüsselwörter: Vascular Endothelial Growth Factor Receptor, Neuropilin-1, 
Apoptose, zerebrovaskuläres System, Mittlere-Cerebrale-Arterie-Okklusions 
(MCAO)-Modell 
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5 Abstract 
Cerebral ischemia is encompassed by vascular apoptosis leading to cerebrovascular 
damage, yet the mechanisms of apoptosis induction and inhibition in the cerebral 
vasculature are not fully understood. We have previously demonstrated inhibition of 
endothelial apoptosis by vascular endothelial growth factor through upregulation of 
poly(ADP-ribose)-polymerase expression. Here, we hypothesized that neuropilin-1, 
an alternative receptor for vascular endothelial growth factor, is a fine-regulator of the 
endothelial response to cerebral ischemia. This study investigated the impact of 
neuropilin-1 on endothelial poly(ADP-ribose)-polymerase expression and in turn, its 
modulatory role in apoptosis inhibition by vascular endothelial growth factor in the 
cerebrovascular system. 
In endothelial cell cultures, neuropilin-1 acted as a co-receptor to vascular endothelial 
growth factor receptor-2. This enhanced poly(ADP-ribose)-polymerase mRNA and 
protein expression induced by vascular endothelial growth factor-A, as demonstrated 
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by incubations with receptor-specific inhibitors and vascular endothelial growth factor 
isoforms. Neuropilin-1 colocalized with vascular endothelial growth factor receptor-2 
and augmented the inhibitory effect of vascular endothelial growth factor / vascular 
endothelial growth factor receptor-2 interaction on apoptosis that was induced by 
adhesion inhibition through the Dv-integrin inhibitor cRGDfV. Neuropilin-1 signal 
transduction involved c-Jun N-terminal kinase and Akt. Cerebral ischemia and 
endothelial apoptosis were investigated in rat models of permanent and temporary 
middle cerebral artery occlusion. Animals were evaluated neurologically and by 
cerebral magnetic resonance imaging for edema formation after 24 hours. In brains 
analyzed by in situ-ligation apoptosis assay and immunohistochemistry, vessels of 
ischemic cerebral hemispheres displayed apoptosis and increased endothelial 
neuropilin-1 and vascular endothelial growth factor receptor-2 expression compared 
to non-ischemic cerebral hemispheres and sham-operated or untreated controls. 
Increased vascular superoxide dismutase-1 and catalase expression indicated 
oxidative stress in the ischemic brain. Of note, endothelial poly(ADP-ribose)-
polymerase expression remained stable during cerebral ischemia despite pro-
apoptotic conditions.  
Neuropilin-1 is upregulated in conditions of imminent endothelial apoptosis to 
reinforce apoptosis inhibition and to modulate vascular endothelial growth factor-
dependent poly(ADP-ribose)-polymerase expression in the cerebral vasculature. We 
propose that neuropilin-1 is a key modulator of vascular endothelial growth factor 
maintaining endothelial integrity during ischemia. Modulating the function of 
neuropilin-1 to target poly(ADP-ribose)-polymerase expression could help to prevent 
endothelial apoptosis in the treatment of cerebral ischemia. 
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6 Introduction 
Neuropilin-1 (NP-1) is an alternative receptor for vascular endothelial growth factor 
(VEGF) (Soker et al., 1998). NP-1 has been described to function as a coreceptor to 
VEGF receptor-2 (VEGFR-2), the main receptor for VEGF on vascular endothelial 
cells (EC) (Zachary, 2001; Neufeld et al., 1999). NP-1 potentiates the effects of 
VEGF-A(165) binding to VEGFR-2 by increasing the cellular response to VEGF 
(Soker et al., 1998) and by generating a stronger VEGFR-2 signal (Ballmer-Hofer et 
al., 2011). VEGF is the strongest apoptosis-inhibiting factor of EC supporting 
endothelial survival and regeneration of vascular integrity. Among the different 
members of the VEGF family, VEGF-A is the most important for the vascular system 
with several splice variants (121, 145, 165, 189, and 206 amino acids) that show 
different receptor affinities. VEGF-A(165) shows the strongest biological activity on 
EC promoting survival, proliferation and migration, but also vascular permeability 
(Zachary, 2001). In the cerebral vascular system, arterial occlusion leads to endo-
thelial apoptosis (Li et al., 1995), followed by the breakdown of the blood brain barrier 
and cerebral edema formation, as previously demonstrated (Gerriets et al., 2004 a; 
Gerriets et al., 2004 b). 
 
Endothelial apoptosis is a characteristic result not only of cerebral ischemic disease, 
but also of atherosclerosis or autoimmune vasculitis (Choy et al., 2001; Winn and 
Harlan, 2005). Endothelial apoptosis and survival are subject to complex regulation 
by pro- and anti-apoptotic factors, the most important anti-apoptotic being VEGF. EC 
survival is governed by growth factors and also by adhesion molecules such as 
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integrins (Choy et al., 2001). We have previously demonstrated apoptosis induction 
through the inhibition of vitronectin-dependent adhesion of endothelial and vascular 
smooth muscle cells with subsequent activation of caspase-3 (Al-Fakhri et al., 2003 
a). Caspases are involved in the transduction of apoptosis-inducing signals to the 
nucleus. Caspase-3 induces typical apoptotic features such as DNA degradation by 
endonucleases or inhibition of DNA repair through cleavage of poly(ADP-ribose)-
polymerase (PARP) (Rossi and Gaidano, 2003). PARP is a nuclear DNA-binding 
enzyme that repairs DNA strand breaks and counteracts pro-apoptotic 
deoxyribonucleases. It is inactivated by active caspase-3 at an early stage of the 
apoptotic process (Duriez and Shah, 1997). In a previous study, we reported that 
VEGF specifically induced PARP expression and activity thereby inhibiting EC 
apoptosis (Hörmann et al., 2011). PARP is also involved in inflammation and 
oxidative stress (Virag, 2005; Aguilar-Quesada et al., 2007) by modulating the activity 
of several transcription factors as promoter binding cofactor, like p53, NF-NB, and 
STATs. The role of PARP in cell death and inflammatory responses depends on the 
cellular activation state. In oxidative stress situations with excessive and unrepairable 
DNA damage, such as acute inflammation, shock, or severe ischemia, overactivation 
of PARP leads to intracellular ATP depletion resulting in necrosis. In the absence of 
overactivation, PARP conveys cellular protection (Virag, 2005; Aguilar-Quesada et 
al., 2007). 
 
There are several indications of a modulatory role for NP-1 in VEGF/VEGFR-2 
interactions. However, the intracellular mechanisms by which NP-1 exerts its effect 
on the endothelial VEGF response remain to be identified. We hypothesized that  
NP-1 modulates PARP expression that is induced by VEGF through VEGFR-2 
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signaling and thereby adapts the cellular response to VEGF. NP-1 could act as a 
protective vascular receptor involved in VEGF-dependent processes such as apop-
tosis inhibition in cerebral ischemia. In this study, we investigated the role of NP-1 in 
the inhibition of endothelial apoptosis by VEGF and the effect on PARP regulation in 
cerebral ischemia. We show that NP-1 is an important modulator of VEGF effects 
through the regulation of PARP expression influencing endothelial survival during 
cerebral insults. 
7 Materials and methods 
7.1 Cell cultures 
Human umbilical vein EC (HUVEC) (PromoCell) and the macrovascular EC line 
EA.hy.926 (Edgell et al., 1983) were cultivated for 2 days (d) to 60-70% confluence 
with endothelial growth medium without VEGF supplement (Promocell), thereafter 
incubated as follows: 
7.2 Incubation protocols 
HUVEC and EA.hy.926 were incubated with recombinant human homo-dimeric 
VEGF-A(165) or VEGF-A(121) 1-100ng/ml (5x10-11 - 5x10-9M) (Peprotech) over 16 
hours (h) to 24h for mRNA isolation, over 20h for apoptosis detection, or over 24h to 
6d (with repeated incubations at intervals of 48h) for protein isolation, respectively.  
After stimulation with VEGF to increase the apoptotic threshold, as previously 
described (Hörmann et al., 2011), apoptosis was induced by incubation with DV-
integrin inhibitor cRGDfV (cyclo-[Arg-Gly-Asp-D-Phe-Val]) 5µg/ml (Bachem) for 24h 
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on vitronectin (2µg/ml)-coated multiwell plates, blocked with 3% BSA (Al-Fakhri et al., 
2003 a).  
To analyze the function of NP-1 and VEGFR-2, the above mentioned cells were 
incubated with VEGF-A(165) 10ng/ml in the presence or absence of the peptide 
inhibitor of NP-1  A7R [ATWLPPR] (Bachem) 10µM and/or the selective VEGFR-2 
tyrosine-kinase inhibitor SU5416 [3-[(2,4-dimethylpyrrol-5-yl)-methylidene]-indolin-2-
one] (Calbiochem) 10µM in the presence or absence of cRGDfV 5µg/ml. 
VEGF signal transduction was studied by VEGF-A(165) 100pg/ml-100ng/ml 
incubation over short time intervals (15-30-60-120min). Involvement of Akt and JNK 
was analyzed by incubation with Akt inhibitors triciribine 10µM, isozyme-selective 
Akti-1/2 1µM or SAPK/JNK inhibitor SP600125 10µM (Calbiochem), respectively,  
and VEGF-A(165) 1ng/ml-100ng/ml.  
Controls were conducted in parallel to all experiments using only EC medium 
(negative control), only VEGF-A(165) 10-100ng/ml (VEGF control) or cRGDfV 
(apoptosis control). 
7.3 Animals and MCAO model 
Ischemia was assessed using a permanent and a temporary middle cerebral artery 
occlusion (MCAO) model, as described previously (Gerriets et al., 2004 b). All 
procedures were in accordance with institutional guidelines and the German animal 
protection legislation. Seventeen male Wistar rats (290 to 350 grams; Harlan 
Winkelmann, Borchen, Germany) were randomly subjected to different treatment 
groups: (a) ischemia through MCAO for 90 minutes, followed by reperfusion (IR) after 
90 minutes (n=8) compared to (b) sham-operation (n=5). These were supplemented 
by the groups (c) permanent ischemia through MCAO occlusion (IO) (n=3) and (d) 
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untreated control animal (n=1). The right external carotid artery was ligated and 
transsected, a 4-0 silicone±coated nylon suture was inserted through the external 
carotid artery stump and advanced into the internal carotid artery beyond the carotid 
bifurcation until reaching the anterior cerebral artery, so that blood flow to the MCA 
was blocked. Reperfusion was induced in IR-animals by removing the suture 90 
minutes after MCAO. Neurological evaluation and scoring were performed at 0, 4 and 
24 h as described elsewhere (Gerriets et al., 2004 b). After 24 hours, animals 
underwent MRI (Bruker PharmaScan 7.0T, 16 cm) under isoflurane anesthesia to 
determine ischemic lesion size. T2-relaxation-time as a marker for brain water 
content and lesion-related midline shift were measured to quantify vasogenic edema 
formation. Computer-aided planimetric assessment of the lesion and hemispheric 
volumes were performed using image analysis software Image J (National Institutes 
of Health, NIH), regions of interest in qT2 were defined in the ischemic lesions with 
PharmaScan software 5.1 (Bruker). After euthanasia, brains were snap-frozen and 
analyzed. 
7.4 Apoptosis detection 
Apoptosis was quantified in cultivated cells by annexin V-FITC/propidium iodide (PI) 
(Immunotech) flow cytometry of 20000 cells/measurement (FACSort, BD 
Biosciences), as previously described (Hörmann et al., 2011). Apoptotic cells were 
considered annexin V+/PI- signals within pre-defined gating criteria.  
In rat brain, apoptosis was detected by in situ-ligation assay (ISL) as described 
previously (Schoppet et al., 2004). It demonstrates the apoptosis-specific form of 
DNA fragmentation, i.e. 3' single-base overhang, double-stranded DNA breaks. 
Briefly, a specific DNA probe was prepared by PCR and purified. Brain transverse 
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cryostate sections (6µm) were acetone-fixed, treated with proteinase K 20 µg/mL, 
then incubated with the digoxigenin (DIG)-labelled DNA fragment and DNA T4 ligase 
(Sigma) in a humidified chamber for 1 h at room temperature. For negative control, 
the DIG-labelled DNA fragment was omitted, for positive control, one slide was 
pretreated with DNAse I. Probe binding was detected by sheep anti-DIG Fab-
antibody conjugated to alkaline phosphatase (Roche, Mannheim, Germany, 1:500). 
Color development was performed with NBT/BCIP (nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate) and 1 mM levamisole (Sigma) for 70 min.  
7.5 Western Blot 
Protein was isolated with AllPrep RNA/protein kit (Qiagen) for cells or RIPA buffer 
(50mM Tris pH 8,0 containing 150mM NaCl, 1% NP-40, 0,5% sodium deoxycholat, 
0,1% SDS, protease inhibitor, Complete, Roche) for tissue lysates. Protein 
concentration was determined with bicinchoninic acid reagent (Thermo-Scientific) at 
562nm. Electrophoresis and blotting was performed as described before (Hörmann et 
al., 2011). Primary antibodies employed were rabbit anti human NP-1 (monoclonal, 
Epitomics, 1:1000) and goat-anti-human PARP (R&D-Systems, 0.4µg/ml). All blots 
were normalized to E-actin as loading control stained with mouse-anti-E-actin (clone 
AC-15, Sigma, 1:20.000). Signal transduction molecules were detected with rabbit 
antibodies against Bcl-2, Akt, phospho-Akt (Ser473/Thr308), SAPK/JNK, phospho-
SAPK/JNK (Thr183/Tyr185), ERK1/2, phospho-ERK1/2 (Thr202/204), p38 MAPK, 
and phospho-p38 MAPK (Thr180/Tyr182) (Cell Signaling, 1:500). Western blots were 
evaluated by automated densitometry using the gel analyzing function of Image J 
software (NIH), as previously described (Gassmann et al., 2009). In Bcl-2 blots, only 
one specific band was detected and evaluated. In NP-1 blots, the 130 kDa band 
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representing the membrane-bound receptor was evaluated, other bands at 90 and 75 
kDa representing soluble NP-1 without receptor function (Gagnon et al., 2000; 
Cackowski et al., 2004) found in individual IR and IO animals were excluded from 
analysis. In PARP blots, the band at 116 kDa corresponding to intact PARP was 
evaluated, other bands at 89 and 24 kDa corresponding to inactive PARP cleavage 
products (Duriez and Shah, 1997) that are found in apoptotic specimens were 
excluded, as previously described (Hörmann et al., 2011). 
7.6 Real-time RT-PCR 
PARP-1 mRNA was quantified by real-time polymerase chain reaction (PCR) using 
Rotorgene (Corbett). mRNA was isolated with AllPrep RNA/protein kit (Qiagen) or 
TriFast reagent (Peqlab) and the concentration calculated from OD260. After DNAse I 
(Invitrogen) treatment and inactivation, reverse transcription (RT) was performed with 
Omniscript RT kit (Qiagen). PARP-1 real-time PCR was conducted as recently 
described (Hörmann et al., 2011). 
PARP-1 copy numbers, calculated from threshold cycle (CT) values, were determined 
by means of serially diluted external standards that were synthesized by PCR and 
subsequent purification (Al-Fakhri et al., 2003 b). Results were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. 
7.7 Immunocyto- and immunohistochemistry 
HUVEC grown on vitronectin-coated (2µg/ml) glass cover slips were incubated in the 
presence or absence of VEGF-A(165) 10ng/ml for 2d. Cells were fixed with 4% 
formaldehyde/PBS, incubated with Image-iT FX-signal enhancer (Invitrogen), then 
with mouse-anti-human VEGFR-2 (Santa Cruz, clone Y-23, 1µg/ml) and rabbit-anti-
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human NP-1 (5µg/ml) antibodies 16h at 4°C, thereafter with Alexa Fluor 488- and 
Cy3-labeled secondary antibodies 1h and DAPI 2µg/ml 20min, finally covered with 
ProLong Gold antifade reagent (all Invitrogen). Negative controls were conducted 
with an irrelevant primary antibody or PBS. Immunofluorescence was analyzed by 
means of an AxioVision microscope with optical sectioning using ApoTome.2 
structured illumination technology (Zeiss). 
Transverse cryostat sections (6µm) were acetone-fixed, incubated with 5% normal 
serum/PBS, then with primary antibodies: goat anti-PARP (R&D-Systems, 1:20), goat 
anti-VEGF (R&D-Systems, 1:50), mouse anti-VEGFR-2 (Santa Cruz, clone Y-23, 
1µg/ml), rabbit anti-NP-1 (Invitrogen, 5µg/ml), rabbit anti-cleaved caspase-3 (R&D-
Systems,1:1000), goat anti-catalase (R&D Systems, 0,5µg/ml) or rabbit anti-
superoxide dismutase-1 (SOD-1) (Santa Cruz, FL-154, 10µg/ml) as markers of 
oxidative stress, rabbit anti-von-Willebrand-factor (Dako, 1:200) for 2-16h at 4°C. 
Subsequently, slides were incubated with biotinylated secondary antibodies, 
streptavidin-alkaline phosphatase-conjugate, Fast Red, and Mayer's haemalum 
counterstaining (all Sigma). Negative controls were conducted with an irrelevant 
primary antibody or PBS. Immunostaining was semiquantitatively evaluated by two 
investigators. 
7.8 Statistics 
For all analyses, 3 to 7 independent experiments were performed in triplicate (PCR) 
or duplicate (all other experiments) and results were expressed as mean +/-SD. 
Histological specimens were evaluated semi-quantitatively by light microscopy at 
200-fold magnification through two experienced investigators independently: 
Immunohistochemical data were analyzed by counting the number of positive cells 
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(with a specific, bright-red staining) and identifying the cell type, the apoptotic index 
by counting the number of ISL positive (dark-blue) nuclei, both in four fields of view at 
200-fold magnification per hemisphere and calculating the mean percentage +/-SD, 
respectively. In unpaired, two-tailed Student's t-test, p<0.05 indicated significant 
differences, p<0.01 indicated highly significant differences. 
8 Results 
NP-1 increases apoptosis inhibition induced by VEGF/VEGFR-2 interaction 
Preincubation of HUVEC or EA.hy.926 cells with VEGF-A(165) 1-100ng/ml resulted 
in a significant reduction of the apoptotic rate compared to non-VEGF-treated cells. 
VEGF-A(165) increased endothelial resistance to apoptosis induced by cRGDfV that 
inhibits integrin binding to the vitronectin matrix in HUVEC (Fig. 1A) and EA.hy.926 
cells. The strongest increase in apoptosis resistance was demonstrated for pre-
incubation with VEGF-A(165) over 6d (at 48h-intervals) compared to 24h, matching 
our previous results (Hörmann et al., 2011). Preincubation with VEGF-A(121) 
reduced EC apoptosis induced by cRGDfV significantly less than VEGF-A(165), yet 
increased the resistance to apoptosis (Fig. 1A). VEGF-A(121) binds predominantly to 
VEGFR-2, but has neglectable binding affinity to NP-1, whereas VEGF-A(165) binds 
both receptors (Zachary, 2001). Incubation with VEGF-A(165) alone had no influence 
on the apoptotic rate, whereas VEGF-A(121) slightly increased apoptosis compared 
to the negative control (Fig. 1A). Incubations with receptor inhibitors SU5416 10µM 
and/or A7R 10µM, selective antagonists of VEGFR-2 or NP-1, respectively, revealed 
that blocking NP-1 had no significant influence on the induction of apoptosis 
resistance through VEGF-A(165) in the presence of cRGDfV. However, simultaneous 
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inhibition of VEGFR-2 and NP-1 or blocking VEGFR-2 alone, respectively, abolished 
the apoptosis inhibiting effect of VEGF (Fig. 1B). Therefore, NP-1 signaling alone in 
the presence of VEGFR-2 inhibitor could not prevent apoptosis induction indicating a 
role for NP-1 as the coreceptor of VEGFR-2. Negative controls (Fig. 1B), A7R 
inhibitor controls or incubations only with VEGF-A(165) (data not shown) displayed a 
low apoptotic rate. Incubation with SU5416 alone or A7R together with SU5416 with 
or without VEGF showed a small, but non-significant amount of apoptosis induction 
compared to the negative control (Fig. 1B). Taken together, NP-1 augmented the 
anti-apoptotic VEGF effect conveyed through VEGF/VEGFR-2 interaction as 
demonstrated by incubations with VEGF isoforms, but importantly, NP-1 did not exert 
an independent apoptosis-inhibiting effect as shown by inhibitor experiments.  
 
NP-1 augments the induction of PARP expression by VEGF 
In HUVEC, incubation with VEGF-A(165) 1-100ng/ml over 6d at 48h-intervals caused 
a significantly higher increase in intact PARP protein (116kD), maximum 2.2-fold, 
compared to incubation with VEGF-A(121) 1-100ng/ml, maximum 1.8-fold, as 
demonstrated by Western blot densitometry normalized to E-actin (Fig. 2A). Real-
time RT-PCR revealed a significant, 3.7-fold increase in PARP-1 mRNA production 
normalized to the house keeping gene GAPDH mRNA after incubation with VEGF-
A(165) for 16h compared to negative control preceding the increase in PARP protein. 
VEGF-A(121) induced a 2.8-fold increase in PARP mRNA that was smaller than the 
VEGF-A(165) effect (Fig. 2A). Therefore, binding of both receptors by VEGF-A(165) 
induced a stronger PARP response than binding of predominantly VEGFR-2 by 
VEGF-A(121). This is indicative of NP-1's role as a VEGFR-2 coreceptor.  
 17 
Incubation with VEGF-A(165) and the VEGFR-2 inhibitor SU5416 showed a 
significant reduction of PARP protein expression compared to incubation with VEGF-
A(165) alone (Fig. 2B). Coincubation of VEGF-A(165) with the NP-1 inhibitor A7R 
showed a comparable increase in PARP protein compared to control as incubation 
with VEGF alone indicating that NP-1 inhibition (in the absence of VEGFR-2 
inhibition) had no effect on the regulation of PARP by VEGF. In contrast, combined 
incubation of VEGF-A(165) with A7R and SU5416 further reduced PARP protein 
compared to incubation with VEGF and SU5416 (Fig. 2B). Incubations with A7R 
and/or SU5416 alone (inhibitor controls) had no effect on PARP protein expression 
(Fig. 2B). The increase in PARP-1 mRNA production (normalized to GAPDH mRNA) 
through incubation with VEGF-A(165) was significantly reduced by coincubation of 
VEGF with SU5416 or with A7R and SU5416, respectively. Incubation with VEGF 
and A7R lead to a small, yet significant reduction of PARP mRNA compared to 
VEGF incubation. Inhibitor controls showed no influence on PARP mRNA production 
(Fig. 2B). Thus, NP-1 was demonstrated to augment VEGF-dependent induction of 
PARP expression as a coreceptor to VEGFR-2. These results were reproduced in 
the EC line EA.hy.926.  
 
VEGF has previously been described to induce the intracellular apoptosis inhibitor 
Bcl-2 thereby reducing endothelial apoptosis (Gerber et al., 1998 a). In the present 
study, incubation with VEGF-A(165) 10ng/ml produced a 1.2-fold increase in Bcl-2 
protein that did not reach statistical significance. This increase was smaller than the 
significant elevation in PARP expression induced by VEGF-A(165) (Fig. 2C). This 
finding underlined the relevance of the VEGF effect on PARP expression as 
compared to Bcl-2 expression in the context of apoptosis inhibition. 
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VEGF-dependent signal transduction leading to the induction of PARP expression 
was found to be mediated by phosphorylation of Akt and JNK, as demonstrated by 
Western blot of phosphorylated kinase correlated to total kinase. MAPK p38 and 
ERK1/2 did not show phosphorylation following stimulation with VEGF-A(165) (Fig. 
2D). These results were supported by experiments with Akt inhibitors triciribine and 
Akti-1/2 as well as SAPK/JNK inhibitor SP600125 incubated with VEGF-A(165). 
Therefore, VEGF-A(165) signaling via VEGFR-2 and NP-1 is conveyed by Akt and 
JNK activation. 
 
NP-1 expression colocalizes with VEGFR-2 upon VEGF stimulation and is 
abolished by apoptosis 
VEGFR-2 and NP-1 were expressed on the cell membrane and uniformly distributed 
in the cytoplasm of HUVEC cultivated without VEGF supplement (Fig. 3). The 
receptors showed colocalization at several sites of the cell surface, demonstrated by 
immunofluorescence using 3D-scanning technique of an optical sectioning 
microscopic device. Upon stimulation with VEGF, NP-1 colocalized extensively with 
VEGFR-2, the receptors clustered on the cell surface and in the perinuclear space, 
supporting the VEGFR-2 coreceptor function of NP-1 (Fig. 3). Interestingly, in EC 
undergoing apoptosis induced by adhesion inhibition with cRGDfV, immuno-
detectable NP-1 was dramatically reduced and VEGFR-2 distribution was changed to 
a disseminated, less intense staining pattern. Only few perinuclear receptor clusters 
containing colocalized NP-1 and VEGFR-2, probably rests of endocytosed receptor 
clusters, could be demonstrated in cells undergoing apoptosis (Fig. 3). Results in 
EA.hy.926 cells were comparable. This indicated an organizational and functional 
loss of VEGF receptor integrity in cells undergoing apoptosis. 
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Cerebral ischemia is associated with increased NP-1 and PARP expression and 
related to endothelial apoptosis  
The in-vitro data were corroborated by a permanent (IO) and a temporary (IR) rat 
cerebral ischemia model that were characterized by endothelial apoptosis mainly in 
the ischemic hemisphere, as identified by ISL assay. Both models showed vasogenic 
brain edema on the ischemic side, accompanied by tissue destruction that was more 
prominent the IO model. The edematous lesions corresponded to the lesions found 
on MRI. In the IR model that underwent reperfusion after 90 minutes, the number of 
apoptotic endothelial and neuronal cells was significantly increased in the ischemic 
hemisphere as compared to either the contralateral hemisphere or sham-operated 
and untreated controls (Fig. 4A). Individual apoptotic nuclei were detected in the 
contralateral hemisphere in the vicinity of the cerebral midline, possibly as a 
consequence of the space occupying effect due to vasogenic edema formation. 
Comparable results were demonstrated for IO, however, IR showed a higher rate of 
apoptotic cells than IO (Fig. 4A), possibly due to the excessive tissue destruction in 
the ischemic brain of the IO model that reduced the number of intact vessel and 
neurons.  
 
Neurological evaluation and scoring performed at 0, 4 and 24 h as well as cerebral 
MRI after 24 h, evaluating T2-relaxation-time and midline shift, revealed clinical and 
radiological signs of cerebral ischemia with ensuing vasogenic edema formation and 
cerebral infarction in IR or IO exposed animals. The mean ischemic lesion volume, 
as determined by MRI at time point 24 h, was 31.5% ± 18.7% in the IO group and 
37.0% ± 10.1% in the IR group with no statistical difference between the groups 
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(p>0.05). The values were significantly different from sham- and non-operated control 
animals (0.0% ± 0.0%). Clinical scores after MCAO of the IO and IR groups were 
significantly different from sham- and non-operated animals (p<0.01). 
 
Brain sections analyzed by immunohistochemistry showed increased expression of 
NP-1 and VEGFR-2 in the endothelium and of NP-1 in neurons of the ischemic 
hemisphere in IO and IR rat models (Fig. 4B). In the IR model, NP-1 expression of 
neurons and the endothelium was higher on the ischemic than on the contralateral 
side (Fig. 4B), however, only the number of NP-1 positive vessels was significantly 
different (Fig. 4C). In IO and IR, we generally observed a significantly higher vascular 
NP-1 expression in regions of endothelial apoptosis compared to brains of non-
operated and sham-operated animals. VEGFR-2 showed a similar expression pattern 
as NP-1 in vascular structures in the IO and IR model with an increased VEGFR-2 
expression on the ischemic compared to the contralateral side, but no expression in 
neurons (Fig. 4B). PARP immunostaining was increased in both hemispheres in the 
endothelium as well as in neurons compared to sham-operated and non-operated 
animals (Fig. 4B). In the IR model, PARP immunostaining was significantly higher in 
the neurons on the ischemic side than on the contralateral side; for EC, there was no 
difference between the hemispheres (Fig. 4C). However, the PARP antibody detects 
intact PARP and its degradation products so that an increased PARP 
immunoreactivity might also be due to neuronal apoptosis induction in the ischemic 
region. VEGF expression of pial and glial cells as well as individual neurons in the 
ischemic hemisphere and weaker in the contralateral hemisphere was demonstrated. 
In the ischemic hemisphere, increased immunostaining of activated (cleaved) 
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caspase-3, catalase (Fig. 4B) and SOD-1 expression was found. Von Willebrand 
factor staining demonstrated the integrity of the endothelial lining (Fig. 4B).  
Whole tissue lysates separately prepared from both hemispheres of every individual 
animal showed an increased NP-1 protein expression in the IR model compared to 
the controls as demonstrated by densitometry of Western blots. NP-1 expression was 
higher in the contralateral hemisphere of the IR model compared to the ischemic 
hemisphere (Fig. 4D). However, the tissue lysates consisted of whole brain tissue 
and did not allow for differentiation of cell types. PARP protein levels were almost 
identical on both sides and remained unaltered compared to the control animals 
(p>0.05) (Fig. 4D). Note that an unchanged PARP expression under the pro-
apoptotic conditions of ischemia indicates a net increase in PARP expression, since 
PARP is degraded immediately during apoptosis induction. In summary, NP-1 
together with VEGFR-2 and PARP are increased in cerebral ischemia in the context 
of imminent vascular and neuronal apoptosis. 
9 Discussion 
Vascular apoptosis is a consequence of cerebrovascular ischemia, but in contrast to 
neuronal apoptosis, vascular apoptosis in the brain has not been intensively 
investigated. However, protective therapeutic strategies for the cerebrovascular 
system warrant the characterization of vascular apoptosis inhibition to understand the 
regulation of endothelial integrity (Broughton et al., 2009). This study investigated 
mechanisms underlying cell survival in the vasculature in cerebrovascular ischemia. 
Occlusion of cerebral vessels first leads to increased endothelial permeability and 
temporary impairment of the blood-brain-barrier (Dirnagl et al., 1999), induced by 
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VEGF as an early response to hypoxia (Schoch et al., 2002). VEGF has both, 
beneficial and negative effects on the blood-brain-barrier: Next to inducing 
hyperpermeability, it is the strongest anti-apoptotic factor for vascular EC (Zachary, 
2001) and promotes endothelial migration and proliferation (Kowanetz and Ferrara, 
2006; Ferrara, 2009). However, VEGF-induced hyperpermeability can be adapted 
quickly through the involvement of vesiculo-vacuolar organelles that regulate 
intracellular fluid and molecule transport (Teesalu et al., 2009). When the cerebral 
blood flow is restored within a short time period, the changes in the endothelial 
barrier are reversed. Longer lasting interruptions in perfusion, i. e. 90 minutes of 
ischemia followed by reperfusion, lead to apoptosis of the vascular endothelium (Li et 
al., 1995). This encompasses the breakdown of the blood-brain-barrier with 
consequent cerebral edema and neuronal damage (Dirnagl et al., 1999; Gerriets et 
al., 2004 a). Mechanisms inhibiting endothelial apoptosis therefore not only increase 
endothelial resistance to pro-apoptotic stimuli, but also support vascular integrity and 
may partly or completely prevent breakdown of the blood-brain-barrier in situations of 
vascular stress (Fisher, 2008). 
 
Endothelial apoptosis in cerebral ischemia is induced by the extrinsic apoptosis 
pathway with caspase-8 and caspase-3 activation (Zhou et al., 2004). One of the 
mechanisms by which endothelial apoptosis is prevented physiologically is an 
increase in apoptosis resistance induced by VEGF that counteracts the caspase 
pathway by regulating PARP expression (Hörmann et al., 2011). In the present study, 
apoptosis was induced by the Dv-integrin-specific adhesion inhibitor cRGDfV as a 
well documented approach to apoptosis induction through caspase-3 activation (Al-
Fakhri et al., 2003 a) that in turn cleaves and inactivates PARP (Virag, 2005). PARP 
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is a DNA-repair enzyme counteracting pro-apoptotic stimuli, but it is also a cofactor to 
transcription factors associated with inflammation like NF-NB and STATs (Aguilar-
Quesada et al., 2007). The exact mechanisms by which PARP counteracts apoptosis 
have not been elucidated, whether by its DNA-regenerating function or by the 
regulation of gene expression (Virag, 2005). However, PARP is a two-faced molecule 
that can also cause necrosis when excessive cellular stress occurs (Aguilar-Quesada 
et al., 2007). PARP has also been attributed a role in inflammatory responses. Which 
of its functions PARP exerts depends on the cell's actual activation state (Virag, 
2005; Aguilar-Quesada et al., 2007). 
 
Since VEGF can exert these different effects on the vascular system, its function 
needs to be fine-regulated to adapt to situative responses. A possible candidate 
molecule could be NP-1, a transmembrane, non-tyrosinkinase VEGF receptor, that 
influences the interaction of VEGF with its main receptor, the tyrosinkinase receptor 
VEGFR-2 (Soker et al., 1998; Soker et al., 2002). NP-1 was first described as a 
semaphorin receptor and neuronal cell guidance molecule (Fujisawa and Kitsukawa, 
1998) and was subsequently identified to be a VEGFR-2 co-receptor in VEGF-A(165) 
binding during angiogenesis (Soker et al., 1998; Soker et al., 2002). However, indivi-
dual reports have attributed an independent receptor function to NP-1 on EC (Wang 
et al., 2007; others reviewed in Ylä-Herttuala et al., 2007) and on fibroblasts (Kim et 
al., 2006). NP-1 is also expressed on different non-vascular cells like neurons, T-cells 
and dendritic cells (Lepelletier et al., 2007; Gu et al., 2003) and plays a role in cancer 
cell migration (Jia et al., 2010). NP-1 transgene and gene deletion mouse models 
indicated its essential role in angiogenesis, capillary formation, and in the develop-
ment of the heart, aorta and large blood vessels (Kitsukawa et al., 1997; Kawasaki et 
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al., 1999). In the brain of NP-1 overexpressing mouse embryos, excess and dilated 
vessel formation was identified indicating a role for NP-1 in brain EC migration, 
proliferation, survival, and angiogenesis (Kitsukawa et al., 1995). 
 
The role of NP-1 in disease has predominantly been investigated in tumor 
angiogenesis (Liu et al., 2002; Eccles and Welch, 2007), but its role as a VEGF 
receptor in (cerebro-)vascular pathologies is largely unknown. NP-1 expression has 
been related to neovascularization and angiogenesis in the longer-term course of 
ischemic lesion remodeling in the rat or mouse model (Zhang et al., 2001; Beck et 
al., 2002), but otherwise no evidence exists on the role of NP-1 in acute 
cerebrovascular disease. We hypothesized that NP-1 represents the fine-regulating 
element in the VEGF/VEGF receptor system modulating the VEGF response of the 
endothelium. In this study, we found evidence for the enhancement of important 
effects of VEGF by NP-1. VEGF-dependent apoptosis inhibition and induction of 
PARP expression transduced by VEGFR-2 were augmented by NP-1. Endothelial 
NP-1 and VEGFR-2 expression was found to be increased in cerebral ischemia in 
relation to apoptosis and PARP expression. 
 
NP-1 was characterized as a coreceptor to VEGFR-2 in VEGF-A(165)-dependent 
apoptosis inhibition and upregulation of PARP expression: VEGF-A(121) that binds 
predominantly to VEGFR-2 (Soker et al., 1998) reduced apoptosis significantly less 
than VEGF-A(165) that binds to VEGFR-2 and NP-1. VEGF-A(165) was first 
described as the only VEGF form that binds to NP-1 on EC (Soker et al., 1998), 
lateron binding of VEGF-A(121) to NP-1 was described although without binding 
enhancement of VEGF-A to VEGFR-2 (Whitaker et al., 2001; Pan et al., 2007). 
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VEGF-A(121) actually lacks the NP-1 binding site in exon 7 found in VEGF-A(165) 
(Zachary, 2001), but VEGF-A(121) might bind to NP-1 via the C-terminal region (Pan 
et al., 2007). In this study, incubations with VEGFR-2 and NP-1 inhibitors supported 
the VEGFR-2 coreceptor function of NP-1 for apoptosis inhibition as well as for 
PARP expression. VEGF signaling via both receptors was transduced by Akt and 
JNK activation as shown by detection of kinase phosphorylation and by Akt and JNK 
inhibitor experiments. 
 
Close functional association of NP-1 and VEGFR-2 on EC (Soker et al., 1998; 
Giraudo et al., 1998; Petrova et al., 1999) is reflected in the colocalization of both 
receptors that we demonstrated particularly after VEGF stimulation. The VEGF-
induced clustering of VEGFR-2 and NP-1 in the perinuclear space may originate from 
endocytosed receptor complexes, since NP-1 is internalized together with VEGFR-2 
upon VEGF-A(165) stimulation forming a functional receptor complex localized to 
endocytic vesicles containing Rab11 (Ballmer-Hofer et al., 2011). Additionally, 
intracellularly localized NP-1 may be associated with vesiculo-vacuolar organelles 
that are responsible for VEGF-induced transcellular transport (Teesalu et al., 2009). 
Unexpectedly, the expression pattern of the VEGF receptors changed dramatically in 
cells undergoing programmed cell death with an almost complete disappearance of 
immunodetectable NP-1 and a disseminated, weak VEGFR-2 expression. The 
disassembly of VEGF receptors during apoptosis may point to a loss of VEGF 
responsiveness of EC, since signal enhancement by NP-1 is abolished. The NP-1 
decrease may be caused by receptor internalization and degradation or alternatively 
by receptor shedding: ADAM-10 has been described to shed NP-1 from EC releasing 
soluble NP-1 into the circulation, whereas ADAM-17 is the sheddase of VEGFR-2; 
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NP-1 shedding is not inducible by VEGF in contrast to VEGFR-2 (Swendeman et al., 
2008). Shedding of VEGF receptors supplies soluble NP-1 to more distant vascular 
sites, remarkably, soluble NP-1 acts as VEGF-antagonist by binding VEGF-A(165) 
(Gagnon et al., 2000). Reduction of cellular NP-1 enhances the endothelial 
susceptibility to apoptosis, this effect might be increased when NP-1 is released in its 
soluble form thereby inhibiting VEGF functions. 
 
Bcl-2, an inhibitor of the intrinsic pathway of apoptosis, has previously been identified 
as a target of VEGF to reduce endothelial apoptosis (Gerber et al., 1998 a). In rheu-
matoid synovia, twofold upregulation of Bcl-2 by VEGF through NP-1 has also been 
described thereby protecting from apoptosis (Kim et al., 2006). However, since 
endothelial apoptosis is mainly induced via the extrinsic pathway in cerebral ischemia 
(Zhou et al., 2004) and in atherosclerotic vascular remodeling (Al-Fakhri et al.,  
2003 a), a caspase mediator like PARP is more likely to influence EC apoptosis. As a 
control experiment, we investigated Bcl-2 regulation by VEGF, but did not find the 
two- to threefold increase in Bcl-2 protein levels described previously (Gerber et al., 
1998 a) in our experimental settings. Instead, the effect of VEGF on the expression 
of Bcl-2 was smaller than that on PARP. Upregulation of PARP was therefore shown 
to be the more prominent effect of VEGF in EC. 
 
In the rat MCAO model, we found that upregulation of endothelial NP-1 and VEGFR-
2 occurred in the short-term course of cerebral ischemia within 24 hours after 
occlusion or occlusion-reperfusion in the vicinity of cerebral infarcts. These regions 
were characterized by endothelial apoptosis and detection of cleaved caspase-3. 
Surprisingly, NP-1 and VEGFR-2 were upregulated not only in the vessels of the 
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infarct-side, but also of the contralateral hemisphere. Overall hemispheral expression 
analyzed from tissue lysates indicated that the expression of NP-1 protein seemed to 
be significantly higher on the contralateral side, possibly because of a higher number 
of intact vessels and neurons, since the ipsilateral hemisphere contained the infarct 
area. However, in immunohistochemistry, a slightly, but significantly higher number of 
NP-1 expressing EC was demonstrated on the ischemic side. In the close vicinity of 
apoptotic vessels, endothelial NP-1 and VEGFR-2 expression was highly increased.  
 
For the first time, this study related imminent endothelial apoptosis in vessels to an 
increased expression of NP-1 and VEGFR-2. Previous studies on cerebrovascular 
NP-1 expression had mainly looked into NP-1 changes related to angiogenesis 
during post-ischemic brain remodeling in longer-term animal models: Upregulation of 
NP-1 was demonstrated in neovascularization from 7 to 28 days after focal cerebral 
ischemia in the rat MCAO model with permanent occlusion (Zhang et al., 2001). 
Vascular NP-1 was also described to be induced in the peri-infarct area related to 
angiogenesis during post-ischemic brain remodeling 3 to 7 days after MCAO in the 
mouse model; neuronal and glial NP-1 was increased as well (Beck et al., 2002).  
However, the VEGF/VEGF receptor system is able to respond acutely to vascular 
impairment by upregulation of VEGF expression in the brain: After transient MCAO in 
rats, VEGF expression increases in neurons and pial cells within the first 24 hours 
after reperfusion (Hayashi et al., 1997). VEGF mRNA is upregulated by microglia and 
macrophages in the ischemic area within the first hours after MCAO (Plate et al., 
1999). Both VEGF isoforms, VEGF-A(165) and -A(121), are detected after chronic or 
acute cerebral hypoperfusion, with a predominance of the NP-1-binding isoform 
VEGF-A(165) (or VEGF-A(164) in the rat) (Hai et al., 2003; Hayashi et al., 1997). In 
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the present study, endothelial VEGF immunoreactivity was demonstrated in brain 
vessels on the infarct and the contralateral side. This VEGF could be bound locally to 
VEGF receptors, as suggested for the fast increase after cerebral ischemia (Plate et 
al., 1999). As to VEGFR-2, previous studies in the rat model did not identify an in-
creased endothelial expression during acute or chronic cerebral ischemia (Hai et al., 
2003; Plate et al., 1999), although this does not entirely fit to the described increase 
in EC-bound VEGF. In contrast, in the mouse MCAO model, strong upregulation of 
vascular VEGFR-2 was found 3 days after ischemia (Beck et al., 2002).  
Vascular apoptosis is induced by pro-apoptotic factors or by radical oxygen species 
(ROS) (Fisher 2008; Olmez and Ozyurt, 2012; Al-Fakhri et al., 2003 a) as a result of 
oxidative stress caused by cerebral ischemia. Oxidative stress reactively induces 
catalase and SOD-1 expression (Slemmer et al., 2008; Facchinetti et al., 1998), both 
of which were found here in the vessels of the ipsilateral hemisphere. Taken 
together, oxidative stress produced by ischemia could lead to a reactive upregulation 
of anti-apoptotic systems, such as the VEGF/VEGF receptor system, thereby causing 
the widespread increase of VEGF receptors in the brain. The increase in VEGF may 
be an anti-apoptotic response to brain injury, since VEGF can by itself induce 
vascular expression of NP-1 via VEGFR-2 (Oh et al., 2002). 
 
PARP immunoreactivity was increased in vessels and neurons after ischemia 
compared to control animals with an identical expression level in both hemispheres in 
whole tissue lysates. Since PARP is degraded immediately during apoptosis (Virag, 
2005; Aguilar-Quesada et al., 2007), stable PARP expression in regions of apoptosis 
during cerebral ischemia indicated a net increase in PARP expression, possibly 
induced by VEGF (Hörmann et al., 2011). This may reflect a short-term, situative 
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response to imminent vascular and neuronal apoptosis to prevent brain damage 
induced by ischemia. However, overactivated PARP can also cause cellular damage, 
since PARP can switch from DNA repair to the enhancement of inflammation and 
oxidative stress (Virag, 2005; Aguilar-Quesada et al., 2007). As a result of ischemia, 
oxidative stress could lead to an increased risk of PARP overactivation and necrotic 
cell death. Induction of PARP expression by VEGF must therefore be controlled to 
avoid PARP overactivation. Since NP-1 modulates the VEGF-dependent 
upregulation of PARP, NP-1 ensures a regulated endothelial response to ischemia 
and apoptosis. NP-1 may therefore represent the best candidate for a key modulator 
ensuring the maintenance of endothelial integrity in cerebrovascular diseases. 
 
Understanding the mechanisms of apoptosis inhibition in the cerebral vasculature 
could ultimately lead to particular or supplemental therapies targeting the 
endothelium to prevent apoptosis. Modulation of the VEGF/VEGF receptor system 
through NP-1, targeting PARP expression and endothelial apoptosis, is a promising 
strategy for post-stroke treatment in the management of cerebral ischemia. 
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10 Figures and figure legends 
Fig. 1. Endothelial resistance to apoptosis is augmented by the vascular endothelial 
growth factor (VEGF) receptor neuropilin-1 (NP-1).  
 (A) Pre-incubation of HUVEC with VEGF-A(165) 10ng/ml (6d, 48h-intervals) 
significantly reduced apoptosis induced by cRGDfV 5µg/ml compared to cells not 
pre-incubated with VEGF. VEGF-A(121) 10ng/ml that binds predominantly to VEGF 
receptor-2 (VEGFR-2) showed a significantly smaller effect on apoptosis inhibition 
than VEGF-A(165) that binds both receptors indicating an increase of the VEGF 
effect through the involvement of NP-1. VEGF-(A165) alone did not influence 
apoptosis, but VEGF-A(121) alone lead to a small increase in apoptosis underlining 
the importance of NP-1 for EC survival.  
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 (B) The impact of NP-1 on apoptosis inhibition was supported by experiments with 
VEGFR-2 inhibitor SU5416 and NP-1 inhibitor A7R. Pre-incubation of HUVEC with 
VEGF-A(165) 10ng/ml over 6d inhibited cRGDfV-induced apoptosis, this was blocked 
by co-incubation with SU5416 10µM or the combination of SU5416 with A7R 10µM. 
In contrast, A7R had no effect on apoptosis inhibition in cells pre-incubated with 
VEGF-A(165) compared to incubation with VEGF and cRGDfV. Incubations with 
VEGF-A(165) and inhibitors (without cRGDfV) showed no apoptosis induction 
through A7R and a small, non-significant rise in the apoptotic rate through SU5416 or 
both inhibitors in the presence of VEGF. Control incubations with inhibitors alone 
showed no significant induction of apoptosis, incubations with inhibitors and cRGDfV 
had results similar to cRGDfV alone (data not shown). Data in (A) and (B) are mean 
+/- standard deviation of 4-5 independent experiments. Statistical significance of 
differences is indicated by a p-value of <0.05 (t-test). 
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Fig. 2. NP-1 increases PARP expression induced by VEGF.  
  
(A) VEGF-A(165) 10ng/ml induced a significantly stronger increase in PARP protein 
than VEGF-A(121) 10ng/ml demonstrated by Western blot and automated 
densitometry. PARP protein was normalized to E-actin as loading control. 
Additionally, VEGF-A(165) had a grea-ter effect on PARP mRNA production than 
VEGF-A(121), quantified by real-time RT-PCR and normalized to GAPDH mRNA 
copy. These data indicate a co-receptor role for NP-1 augmenting the effect of 
VEGF/VEGFR-2 interaction on PARP expression.  
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(B) Incubation with VEGF-A(165) and SU5416 (VEGFR-2 inhibitor) demonstrated a 
significantly reduced expression of PARP protein compared to incubation with A7R 
(NP-1 inhibitor) and VEGF or with VEGF alone. Combined incubation A7R and 
SU5416 with VEGF-A(165) further reduced PARP protein emphasizing the 
coreceptor function of NP-1 in PARP gene induction. PARP mRNA production was 
influenced accordingly by incubation with VEGF-A(165), SU5416 and A7R, quantified 
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by real-time RT-PCR and normalized to GAPDH mRNA. However, PARP mRNA 
production levels from incubations with VEGF-A(165) and SU5416, A7R or both 
inhibitors, respectively, were not statistically different. Control incubations with 
inhibitors only had no influence on PARP protein or mRNA expression.  
 
(C) VEGF-A(165) induced the expression of the anti-apoptotic intracellular protein 
Bcl-2, however, the expression level was significantly smaller than that of PARP 
protein and did not reach statistical significance compared to negative control.  
Data in (A), (B) and (C) are the means of 3 independent experiments. Representative 
blots of experiments are supplemented to the densitometry data. 
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(D) Analysis of signal transduction revealed activation of Akt and JNK, whereas 
ERK1/2 and MAPK p38 remained unphosphorylated. Short term incubations over 15-
120 min were carried out with VEGF-A(165) 10-100ng/ml and analyzed by Western 
blot automated densitometry of the respective phosphorylated to total kinase 
proteins. Data are the means of 5 independent experiments.  
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Fig. 3. The colocalized receptors VEGFR-2 and NP-1 change their expression 
pattern upon VEGF stimulation and during apoptosis induction. In control incubations 
of HUVEC without VEGF ("contr."), VEGFR-2 and NP-1 were demonstrated on the 
endothelial cell membrane and in the cytoplasm with a disseminated distribution 
pattern and only occasional colocalization. After incubation with VEGF-A(165) 
10ng/ml ("VEGF"), clustering and almost complete colocalization of VEGFR-2 and 
NP-1 was demonstrated by optically sectioned immunofluorescence staining 
(ApoTome.2, Zeiss). Clusters of colocalized receptors we detectable in the cytoplasm 
indicating receptor endocytosis. Apoptosis induction with cRGDfV 5µg/ml ("cRGD") 
dramatically reduced NP-1 expression leaving no NP-1 on the cell surface and only 
few clusters of NP-1 with VEGFR-2 in the perinuclear space. The VEGFR-2 
expression pattern became diffusely distributed in cells undergoing apoptosis. 
VEGFR-2 is stained green (Alexa Fluor 488), NP-1 red (Cy-3), nuclei are stained 
blue (DAPI); 600-fold magnification. The scale bar represents 100 µm. A 
representative example of 3 independent experiments is shown. Individual sites of 
colocalized receptors are indicated by arrows. 
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Fig. 4. Cerebral ischemia of the rat is characterized by endothelial apoptosis and 
changes in the expression of VEGF receptors and PARP.  
  
(A) In the ischemia-occlusion (IO, n=3) and ischemia-reperfusion model (IR, n=8), 
apoptosis was detected by ISL assay. The number of apoptotic cells, especially of 
EC, was significantly higher on the ischemic side of the IR model than of the IO 
model compared to sham-operated (n=5) and untreated controls (n=1). The panels 
show the IR model stained by ISL assay, examples of neuronal tissue (neuron.) and 
vascular endothelium (endoth.) of the ischemic and contralateral side are given 
together with staining controls (pos: positive control, DNAse I pretreatment; neg: 
negative control, no probe). Arrowheads in the upper panels indicate ISL-positive, 
apoptotic neuronal nuclei, arrows in the lower panels indicate the vascular 
endothelium (200-fold magnification). Data in (A) and (C) are means +/- standard 
deviation of two experiments counted by two investigators as described in the text.  
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(B) Cryotome sections of rat brains were stained by immunohistochemistry (alkaline 
phosphastase-conjugate, Fast Red). Representative examples from the ischemic (Is) 
and contralateral (Cl) hemisphere of the IR model and of an untreated, normal animal 
(No) are shown (200-fold magnification). The inserted panels show a close-up of the 
positively marked vessels at higher magnification. Increased VEGFR-2 and NP-1 
immunoreactivity was detected on the endothelium of the ischemic and contralateral 
hemisphere in the IR model. NP-1 immunostaining was also increased in neurons in 
the IR model, especially on the ischemic side, compared to controls. PARP 
immunoreactivity was increased in the endothelium and neurons in IR animals 
compared to controls. Activated, cleaved caspase-3 (act. casp.-3) and catalase were 
increased in the vascular endothelium of the ischemic hemishpere indicating a 
correlation between endothelial apoptosis, increased PARP and NP-1 expression 
with oxidative stress. Catalase (and SOD-1, not shown) were also moderately 
increased in vessels of the contralateral hemisphere. As staining controls, von 
Willebrand factor (positive control for the endothelial lining) and the negative staining 
control (neg. contr.) are shown. The scale bar in (A) and (B) represents 100 µm.  
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(C) Semi-quantitative evaluation of NP-1 and PARP immunostaining revealed a 
highly significant increase in NP-1 and PARP positive endothelial and neuronal cells 
in the IR model on the ischemic (IR ischemic) and contralateral (IR contralat.) side 
compared to non-operated (no op.) and sham-operated (sham-op.) animals. An 
increased number of NP-1 and PARP positive vessels were demonstrated in the 
vicinity of regions of endothelial apoptosis. Comparison of the ischemic and the 
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contralateral hemisphere in IR animals revealed a higher number of NP-1 positive 
neurons and vessels on the ischemic side, but only endothelial expression was 
significantly different between the hemispheres. PARP positive vessels were 
comparably increased in both hemispheres, but a significantly higher count of PARP 
positive neurons was found in the ischemic compared to the non-ischemic 
hemisphere.  
 (D) In separately prepared whole brain tissue lysates of both hemispheres, an 
increased NP-1 protein expression in the IR model was found compared to controls. 
NP-1 expression was higher in the contralateral hemisphere than in the ischemic 
hemisphere demonstrated by Western blot and automated densitometry. PARP 
protein expression was comparably high in the IR model as in controls, no statistical 
difference was found between the ischemic and the contralateral hemisphere. These 
findings indicate a net increase in the production of PARP under pro-apoptotic 
conditions, since PARP is degraded during apoptosis induction. Representative blots 
of individual animals are supplemented to the densitometry data.  
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